PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741312
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741312
Insulin Sensitizers Market is estimated to be valued at USD 23.77 Bn in 2025 and is expected to reach USD 36.7 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 23.77 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 6.40% | 2032 Value Projection: | USD 36.7 Bn |
Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.
Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.
Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.
Insulin Sensitizers Market Detailed Segmentation: